- Conditions
- Netherton Syndrome
- Interventions
- QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle, QRX003-4% Lotion BID
- Drug
- Lead sponsor
- Quoin Pharmaceuticals
- Industry
- Eligibility
- 14 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 5
- States / cities
- San Diego, California • Indianapolis, Indiana • Quincy, Massachusetts + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2137–2160
of 10,535
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Vision, Healthy, Attention
- Interventions
- Blocked Trials, Mixed trials
- Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Newton, Massachusetts
- Conditions
- Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma
- Interventions
- Cediranib Maleate, Cisplatin, Laboratory Biomarker Analysis, Pemetrexed Disodium, Placebo Administration
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2027
- U.S. locations
- 230
- States / cities
- Rogers, Arkansas • Antioch, California • Burbank, California + 148 more
- Conditions
- Melanoma
- Interventions
- Dapansutrile, Pembrolizumab
- Drug
- Lead sponsor
- April Salama, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID, Placebo
- Drug
- Lead sponsor
- vTv Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 47
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Concord, California + 41 more
- Conditions
- ADHD, Parenting
- Interventions
- MomMA Intervention
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Solid Tumors, KRAS Mutation; SOS1
- Interventions
- BI 1701963, Trametinib
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Charlotte, North Carolina • Nashville, Tennessee + 1 more
- Conditions
- Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Carcinosarcoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Carcinosarcoma
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine, Pembrolizumab, Pheresis
- Procedure · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Interventions
- Biospecimen Collection, Drug Withdrawn, Quality-of-Life Assessment, Questionnaire Administration, Tyrosine Kinase Inhibitor
- Procedure · Other · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 25 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 157
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 123 more
- Conditions
- Neoplasms
- Interventions
- Dostarlimab
- Biological
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 729 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Scottsdale, Arizona + 38 more
- Conditions
- Fragile X Syndrome
- Interventions
- Baclofen, Memantine, Roflumilast, Placebo
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- 4D-125 IVT Injection, Observational
- Biological · Other
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 8
- States / cities
- Aurora, Colorado • Gainesville, Florida • Ann Arbor, Michigan + 5 more
- Conditions
- Plaque, Dental, Gingivitis
- Interventions
- Colgate SNaP Total 10/10, 1.5 Taurate, Colgate Great Regular Flavor Toothpaste, Flat Trimmed Extra Clean TB
- Drug · Other
- Lead sponsor
- Colgate Palmolive
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Costa Mesa, California
- Conditions
- Primary Sjogrens Disease
- Interventions
- Efgartigimod PH20 SC, Placebo PH20 SC
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 631 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 42
- States / cities
- Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 36 more
- Conditions
- Advanced Solid Tumors Cancer
- Interventions
- Osimertinib, Nivolumab, Telisotuzumab vedotin, Erlotinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 17 more
- Conditions
- Acute Myocardial Infarction, Coronary Artery Disease
- Interventions
- Physiology-guided NCL PCI, Angiography-guided NCL PCI
- Procedure
- Lead sponsor
- Population Health Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 14
- States / cities
- Los Angeles, California • San Francisco, California • Wichita, Kansas + 10 more
- Conditions
- Obesity, Weight Loss, Delayed Gastric Emptying Following Procedure, Obesity, Mild, Obesity, Morbid, Obesity; Excess Calories
- Interventions
- Bariatric Endoscopic Antral Myotomy
- Procedure
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Fallopian Tube Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Carcinoma, Ovarian High Grade Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Cediranib Maleate, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Questionnaire Administration
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 12 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Durvalumab, Placebo, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Gemcitabine, Surgery
- Drug · Other · Procedure
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 825 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Duarte, California • Orange, California + 25 more
- Conditions
- Malignant Melanoma
- Interventions
- Peginterferon alfa-2b, Temozolomide, Recombinant interferon alfa-2b
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2031
- U.S. locations
- 3
- States / cities
- San Diego, California • Memphis, Tennessee • Houston, Texas
- Conditions
- Adenosine Deaminase Severe Combined Immune Deficiency
- Interventions
- A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme
- Combination Product
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 1 Month and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Cardiovascular Disease
- Interventions
- Vitamin D3, Omega-3 fatty acids (fish oil), Fish oil placebo, Vitamin D3 placebo
- Dietary Supplement · Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 25,119 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hallux Valgus, Bunion
- Interventions
- Lapiplasty
- Device
- Lead sponsor
- Treace Medical Concepts, Inc.
- Industry
- Eligibility
- 14 Years to 58 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 7
- States / cities
- Greeley, Colorado • Ankeny, Iowa • Jefferson City, Missouri + 4 more
- Conditions
- Osteoarthritis, Knee Osteoarthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases
- Interventions
- Exercise for Knee Osteoarthritis Recommendations (Control group), Exercise for Knee Osteoarthritis -(LBPP supported low-load treadmill Walking), Exercise for Knee Osteoarthritis - (Aquatic Walking)
- Other
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois